荃信生物-B(02509.HK)公布,周三(23日)与Caldera Therapeutics订立一项对外授权协议,授予Caldera Therapeutics开发以及商业化QX030N的全球独家许可。公告披露,Caldera Therapeutics获授独家、须支付特许权使用费、可转让、可再授权的权利,以在全球范围内研究、开发、注册、生产及商业化QX030N。作为回报,荃信生物或其指定联属公司将...
Source Link荃信生物-B(02509.HK)公布,周三(23日)与Caldera Therapeutics订立一项对外授权协议,授予Caldera Therapeutics开发以及商业化QX030N的全球独家许可。公告披露,Caldera Therapeutics获授独家、须支付特许权使用费、可转让、可再授权的权利,以在全球范围内研究、开发、注册、生产及商业化QX030N。作为回报,荃信生物或其指定联属公司将...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.